Iridium-Coumarin Anticancer Conjugates

  • ChemPubSoc Europe Logo
  • Author: Angewandte Chemie International Edition
  • Published Date: 06 May 2019
  • Source / Publisher: Angewandte Chemie International Edition/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
thumbnail image: Iridium-Coumarin Anticancer Conjugates

Photodynamic therapy (PDT) for the treatment of cancer is based on the use of non-toxic compounds (photosensitizers, PS) which produce toxic reactive oxygen species that destroy tumor cells when the PS are subjected to light. However, they usually suffer from a strong dependence on the oxygen supply. This makes the treatment of deep hypoxic tumors (i.e., tumors with a low oxygen concentration) difficult.


José Ruiz, University of Murcia and Institute for Bio-Health Research of Murcia (IMIB-Arrixaca), Spain, Viktor Brabec, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic, Vicente Marchán, University of Barcelona, Spain, and colleagues have developed a PS agent (pictured) in which a cyclometalated iridium(III) complex is attached to a far-red emitting coumarin dye. This combines the anticancer activity of IrIII complexes with the photophysical properties of organic dyes. The compound was synthesized by forming an amide bond between a carboxylic acid functional group of the iridium complex and a free amino group of the coumarin dye.


The conjugate has several interesting features for cancer phototherapy, such as aqueous solubility, high cellular uptake, and high photocytotoxicity even under low-oxygen conditions. The compound selectively generates highly cytotoxic superoxide anion radicals upon visible-light irradiation. In the researchers' opinion, iridium-coumarin derivatives could lead to new fluorescent-PDT agents with potential applications in diagnosis and therapy.


 

 

Article Views: 634

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH